Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk of serious hypoglycemia-associated adverse events.1
INITIAL TREATMENT — Metformin is generally preferred for...
- Aceclidine (Vizz) for Presbyopia
- Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs
- Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis
- In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease
- In Brief: Primary Aldosteronism Screening in Patients with Hypertension
- In Brief: Keytruda Qlex – A Subcutaneous Formulation of Pembrolizumab (online only)
- In Brief: Kirsty — An Insulin Aspart Interchangeable with NovoLog (online only)
ISSUE
The FDA has approved Vizz (Lenz Therapeutics), a 1.44% ophthalmic solution of the cholinergic agonist aceclidine, for treatment of presbyopia in adults. Aceclidine has been available in the EU for years for treatment of open-angle glaucoma.
PRESBYOPIA — Presbyopia is a common age-related condition characterized by gradual loss of clear near vision. It is thought to be caused by loss of lens elasticity and weakening of ciliary muscles.
STANDARD TREATMENT — Corrective lenses (glasses and contact lenses) are the first-line treatment for presbyopia.
The muscarinic agonist pilocarpine is available in a 1.25% ophthalmic solution (Vuity) and in a 0.4% ophthalmic solution (Qlosi) for treatment of presbyopia (see Table 1).1,2 Vuity contains the preservative benzalkonium chloride, which can cause irritation; Qlosi does …